|Vectura Group plc|
One Prospect West
United Kingdom - Map
Phone: 44 1249 667700
Fax: 44 1249 667701
Vectura Group plc develops pharmaceutical therapies for the treatment of bronchopulmonary diseases. Its products target various diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company offers ADVATE, a serum-free recombinant factor VIII for haemophilia A; Adept, a 4% icodextrin solution used during surgery to reduce post-surgical adhesions; Extraneal, a solution containing icodextrin for peritoneal dialysis; and Seebri Breezhaler, a long-acting muscarinic antagonist for the treatment of COPD, as well as Asmasal Clickhaler, Asmabec Clickhaler, and Meptin for the treatment of asthma. Its product pipeline comprises QVA149, a fixed-dose combination of indacaterol maleate and glycopyrronium bromide for the treatment of adult patients with COPD; VR315 and VR632 that are inhaled combination therapies for asthma and COPD; VR506, an inhaled corticosteriod for the treatment of asthma; VR496, an inhaled, locally acting treatment for symptoms of inflammatory respiratory disease; and VR040, an inhaled, systemically acting form of apomorphine hydrochloride for treating off episodes associated with advanced Parkinson's disease. The company also provides various drug delivery technology platforms, such as PowderHale, a dry powder inhalation (DPI) formulation technology that is designed to allow aerosolized drug particles to achieve high lung deposition with low-dose variability; GyroHaler and OmniHaler, which are multi-unit dose DPI devices designed to deliver locally acting drugs to the lungs; Clickhaler, a single-dose inhaler; and Duohaler, a dry powder inhaler. It has development collaborations and license agreements with Novartis AG, Sandoz, Baxter International Inc, GlaxoSmithKline, and Tianjin KingYork Group Company Limited. The company was founded in 1997 and is headquartered in Chippenham, the United Kingdom.
|Dr. Christopher Paul Blackwell B.Sc., Ph..D.,
Chief Exec. Officer and Exec. Director
|Mr. Trevor Michael Phillips B.Sc., Ph.D., M.B.A.,
Chief Operations Officer, Pres of US Operations and Director
|Mr. Neil William Warner BA, FCA, MCT,
Non-Exec. Director, Chairman of Audit Committee, Member of Remuneration Committee and Member of Nomination Committee
|Mr. Paul Stephen Oliver ,
Chief Financial Officer and Sec.
|Dr. Karl Keegan BSc MPhil Ph.D., MSc,
Director of Corp. Devel.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in GBp.|